Highly Customized Approach
The Private Capital Markets team at Leerink Partners advises clients on all aspects of debt and equity placement transactions. The group has a strong track record of structuring and executing customized financing solutions across all forms of capital through privately marketed and bespoke transactions. Our dedicated team integrates with Leerink Partners’ investment banking industry specialists to customize a solution that is tailored to each client’s unique circumstances.
In addition to determining an effective and efficient process and strategy, Leerink’s PCM team manages all aspects of execution—from initial positioning to final negotiation. Deep, senior-level relationships with investors spanning the spectrum of debt (e.g. traditional lenders, institutional investors, and specialty credit funds) and equity investors (e.g. venture, growth, buy-out) allow us to deliver on a wide array of financing alternatives.
Recent Transactions
Our Private Capital Markets Team
- Banking
- Management
Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking at Leerink Partners and sits on the Firm’s executive committee.
For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.
Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.
Dan Dubin, M.D., is the Vice Chairman, Co-President, Global Co-Head of Investment Banking at Leerink Partners and sits on the Firm’s executive committee.
For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.
Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.
Caroline Cameron is the Chief Operating Officer of Investment Banking at Leerink Partners.
Prior to joining the Firm in 2024, Caroline was the Chief Operating Officer at Keefe, Bruyette & Woods (KBW, A Stifel Company). Prior to her time at Keefe, Bruyette & Woods, she worked in investment banking at Edgeview Partners (acquired by Piper Jaffrey), and as a research analyst at Fox-Pitt, Kelton and Macquarie Capital.
She earned a B.A. in Psychology and Economics from Hamilton College where she graduated Phi Beta Kappa.
Featured Insights
Tariff Risks Underappreciated: Key Considerations and What Companies are Saying
Tecfidera® Was a Bargain, Price Increases and All
